Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2021-12-13 00:00:00 ET · period of report 2021-12-10 · accession 0001209191-21-069313 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-13 | 2021-12-10 | FATE | Chu Yu-Waye | Senior VP Clinical Development | S - Sale+OE | $51.46 | -7,500 | 130.3K | -5% | -$385.9K |
| D | 2021-12-13 | 2021-12-10 | FATE | Chu Yu-Waye | Senior VP Clinical Development | M - OptEx | $16.32 | +7,500 | 133.3K | +6% | +$122.4K |
| D | 2021-12-13 | 2021-12-10 | FATE | Chu Yu-Waye | Senior VP Clinical Development | M - OptEx | $0.00 | -7,500 | 105.0K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-10 | S | D | 1,045 | $51.08 | 129,216 | D | — | — | (F4) Represents the weighted average sale price of the shares sold ranging from $50.96 to $51.22 per share. |
| 2 | Common | Common Stock | 2021-12-10 | S | D | 600 | $54.58 | 126,763 | D | — | — | (F7) Represents the weighted average sale price of the shares sold ranging from $54.33 to $54.98 per share. |
| 3 | Common | Common Stock | 2021-12-10 | S | D | 5 | $55.54 | 125,758 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-10 | S | D | 1,031 | $53.66 | 126,363 | D | — | — | (F6) Represents the weighted average sale price of the shares sold ranging from $53.10 to $54.02 per share. |
| 5 | Common | Common Stock | 2021-12-10 | S | D | 1,822 | $52.37 | 127,394 | D | — | — | (F5) Represents the weighted average sale price of the shares sold ranging from $52.09 to $52.87 per share. |
| 6 | Common | Common Stock | 2021-12-10 | M | A | 7,500 | $16.32 | 133,258 | D | — | — | |
| 7 | Common | Common Stock | 2021-12-10 | S | D | 2,097 | $49.32 | 131,161 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $48.95 to $49.87 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 7. |
| 8 | Common | Common Stock | 2021-12-10 | S | D | 900 | $50.42 | 130,261 | D | — | — | (F3) Represents the weighted average sale price of the shares sold ranging from $49.96 to $50.89 per share. |
| 9 | Derivative | Stock Option (Right to Buy) | 2021-12-10 | M | D | 7,500 | $0.00 | 105,000 | D | $16.32 · — to 2029-04-15 | 7,500 Common Stock | (F8) The option shall vest as to 25% of the underlying shares on April 15, 2020 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date |